secwatch / observer
8-K/A filed December 18, 2025, 6:59 PM ET ticker LONA CIK 0001620463
M&A confidence high sentiment positive materiality 0.85

Athira Pharma licenses lasofoxifene rights, raises $90M in PIPE financing

LeonaBio, Inc.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

LeonaBio, Inc. issued 5,356,547 shares of common stock to Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors for $6.35 per share.

Security
common stock
Shares
5,356,547 shares
Purchaser
Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors
Consideration
$6.35 per share
Exact text from the filing
Shares, the “ PIPE Shares ”). The purchase price for each PIPE Initial Share (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.35 and the purchase price for each PIPE Pre-Funded Warrant (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.349 per each underlying
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

LeonaBio, Inc. issued pre-funded warrants to purchase 8,816,684 shares of Common Stock; Series A warrants to purchase 23,031,494 shares; Series B warrants to purchase 21,259,842 shar of warrant to Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors for $6.349 per pre-funded warrant (including accompanying warrants); Series A exercise price $6.35 per share; Series B exercise price $7.62 per share.

Security
warrant
Shares
pre-funded warrants to purchase 8,816,684 shares of Common Stock; Series A warrants to purchase 23,031,494 shares; Series B warrants to purchase 21,259,842 shar
Purchaser
Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors
Consideration
$6.349 per pre-funded warrant (including accompanying warrants); Series A exercise price $6.35 per share; Series B exercise price $7.62 per share
Exact text from the filing
Shares, the “ PIPE Shares ”). The purchase price for each PIPE Initial Share (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.35 and the purchase price for each PIPE Pre-Funded Warrant (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.349 per each underlying
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LeonaBio, Inc. entered into PIPE Securities Purchase Agreement with Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors valued at approximately $90 million (effective 2025-12-18).

Action
entry
Agreement
equity purchase
Counterparty
Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors
Value
approximately $90 million
Effective
2025-12-18
Exact text from the filing
On December 18, 2025, Athira Pharma, Inc. (the “ Company ” or “ Athira ”) entered into a securities purchase agreement (the “ PIPE Securities Purchase Agreement ”) with a select group of investors, including Commodore Capital LP (“ Commodore ”), TCG Crossover Management LLC (“ TGCX ”), Perceptive Advisors (“ Perceptive ”) and other accredited investors
View on SEC.gov

Browse all equity issuances →

LeonaBio, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-25-323786
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.